



UNITED STATES
PATENT AND
TRADEMARK OFFICE

Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/091,706	03/05/2002	Ione A. Kourides	25605-2BA/JPW/AJM/DRM

CONFIRMATION NO. 7959

John P. White
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036

FORMALITIES LETTER



OC00000008919597

Date Mailed: 10/08/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center
Initial Patent Examination Division (703) 308-1202



PART 2 - COPY TO BE RETURNED WITH RESPONSE



AD

Box seq
0310

Docket No. 25605-2BA/JPW/AJM/DRM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ione A. Kourides et al.
Serial No. : 10/091,706
Files : March 5, 2002
For : ISOLATION OF A GENE ENCODING HUMAN
THYROTROPIN BETA SUBUNIT

1185 Avenue of the Americas
New York, New York 10036
December 9, 2002

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

Attn: BOX SEQUENCE

Sir:

**AMENDMENT IN RESPONSE TO OCTOBER 8, 2002 NOTICE TO
COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

This Amendment is submitted in response to an October 8, 2002 Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A copy of the Notice is attached hereto as **Exhibit A**. A response to the October 8, 2002 Notice was due December 8, 2002. However, since December 8, 2002 falls on a Sunday, a response the next business day, i.e. Monday, December 9, 2002, shall be considered timely. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:



Applicants: Ione A. Kourides et al.
Serial No.: 10/091,706
Filed : March 5, 2002
Page 2

In the Specification

Please insert the Sequence Listing annexed hereto as **Exhibit B** into the specification.

REMARKS

The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures states that the subject application fails to comply with the requirements of 37 C.F.R. §§1.821-1.825. Accordingly, the Notice requires applicants to submit a Sequence Listing and computer disk.


In response to the Notice, applicants submit a Sequence Listing attached hereto as **Exhibit B** in compliance with the requirements of §§1.821-1.825. In addition, applicants submit herewith the Sequence Listing on the enclosed computer diskette. Moreover, applicants submit as **Exhibit C** a Statement In Accordance With 37 C.F.R. §1.821(f) certifying that the information in the computer readable form, and that in the paper copy are the same.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.


Applicants: Ione A. Kourides et al.
Serial No.: 10/091,706
Filed : March 5, 2002
Page 3

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents P.O. Box 2327 Arlington, VA 22202.


Alan J. Morrison
Reg. No. 37,399

Date

12/8/02

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



#8

Docket No. 25605-2BA/JPW/AJM/DRM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ione A. Kourides et al.
Serial No. : 10/091,706
Files : March 5, 2002
For : ISOLATION OF A GENE ENCODING HUMAN
THYROTROPIN BETA SUBUNIT

1185 Avenue of the Americas
New York, New York 10036
December 9, 2002

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information as the paper copy of the Sequence Listing submitted herewith as **Exhibit B** to the Amendment, and does not introduce new matter.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and beliefs are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Deepro R. Mukerjee
c/o Cooper & Dunham
1185 Avenue of the Americas
New York, New York 10036